US FDA panel to review InterMune's pirfenidone for idiopathic pulmonary fibrosis
This article was originally published in Scrip
Executive Summary
The US FDA's pulmonary-allergy drugs advisory committee will meet on March 9th to review InterMune's NDA for its investigational idiopathic pulmonary fibrosis (IPF) treatment, pirfenidone.